Drug intelligence / Profile preview

9-deazainosine-2',3'-O-ethylidenephosphonate

Development stage: Unknown
Modality: Small Molecules

Overview

9-deazainosine-2',3'-O-ethylidenephosphonate is an experimental small molecule belonging to the pyrrolopyrimidine class, structurally related to purine nucleosides. It acts as an inhibitor of purine nucleoside phosphorylase, a key enzyme in the purine salvage pathway. By inhibiting this enzyme, it may disrupt nucleotide metabolism and has potential antitumor activity. The compound has not been approved for clinical use and remains at the experimental stage with no reported indications or advanced clinical trials[1].

Other names: 9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE

Targets

PNP (Purine nucleoside phosphorylase)

Beyond the preview

Go deeper on 9-deazainosine-2',3'-O-ethylidenephosphonate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9-deazainosine-2',3'-O-ethylidenephosphonate.

Explore the full profile